Exelixis, Inc.
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Drugs in Pipeline
12
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Jul 27, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Cabozantinib
Solid Tumors
prednisone
Prostate Cancer
Everolimus
Pancreatic Neuroendocrine Tumor (pNET)
Cabozantinib tablets
Renal Cell Carcinoma
Abiraterone Acetate
Metastatic Prostate Cancer
XL092
Non-Clear Cell Renal Cell Carcinoma
XL184
Glioblastoma Multiforme
Sorafenib
Hepatocellular Carcinoma
Regorafenib
Colorectal Cancer
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
erlotinib
Carcinoma, Non-Small-Cell Lung
XL820
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cabozantinib | Phase 3 | Solid Tumors | - | - |
prednisone | Phase 3 | Prostate Cancer | - | - |
Everolimus | Phase 3 | Pancreatic Neuroendocrine Tumor (pNET) | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
Abiraterone Acetate | Phase 3 | Metastatic Prostate Cancer | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |